Initial data from ongoing clinical study presented by MD Anderson Cancer Center and Trovagene at AACR-NCI-EORTC International Conferences highlights promise of urine-based, cell-free diagnostics

Findings from studies investigating clinical validity of non-invasive cancer-mutation monitoring platform will be shared for first time at AACR-NCI-EORTC conference on October 21, 2013

Cell-free DNA assay transferred to CLIA laboratory for patient testing

Study to investigate Trovagene's non-invasive cancer monitoring technology using cell-free DNA from urine samples

Rodman & Renshaw 15th Annual Global Healthcare Conference and Stifel Healthcare Conference 2013

Digital PCR system adoption helps create ultra-sensitive cell-free DNA assay

Patent covers methods of detecting cell-free microRNA in urine and blood

Trovagene develops ultra-sensitive cell-free DNA assay

Presentation scheduled on June 27, 2013 at 9:20 a.m. ET in New York

Presentation scheduled on June 6, 2013 at 3:00 p.m. ET in New York

New, non-invasive molecular diagnostic test is easy, fast, and accurate

Presentation scheduled on March 19, 2013 at 12:00 p.m. PT at the Ritz-Carlton Laguna Nigel, in Dana Point, CA

Presentation scheduled on February 13, 2013 at 9:00 a.m. ET at the Waldorf Astoria in New York City

Study with MD Anderson will compare detection of BRAF mutations in urine to biopsy samples, and monitor therapeutic response, outcomes

Renowned molecular geneticist strengthens Trovagene's scientific expertise

COMPANY CONTINUES TO DEVELOP PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE

Issuance of First US NPM1 Patent Triggers Milestone Payment

COMPANY CONTINUES TO EXPAND PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE

Study will compare detection of KRAS mutations in urine to their detection in biopsy samples

Internationally recognized cancer researcher and physician strengthens Trovagene's scientific expertise in cancer genetics

Company plans to establish comprehensive panel of assays to detect oncogene mutations in the urine of cancer patients

- Pharmaceutical and diagnostic sales and marketing executive will provide leadership to accelerate commercial programs -